期刊
CHEMICAL SOCIETY REVIEWS
卷 43, 期 19, 页码 6765-6813出版社
ROYAL SOC CHEMISTRY
DOI: 10.1039/c3cs60460h
关键词
-
资金
- National Institutes of Health
- NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM053386, R01GM053386] Funding Source: NIH RePORTER
BACE1 (beta-secretase, memapsin 2, Asp2) has emerged as a promising target for the treatment of Alzheimer's disease. BACE1 is an aspartic protease which functions in the first step of the pathway leading to the production and deposition of amyloid-beta peptide (A beta). Its gene deletion showed only mild phenotypes. BACE1 inhibition has direct implications in the Alzheimer's disease pathology without largely affecting viability. However, inhibiting BACE1 selectively in vivo has presented many challenges to medicinal chemists. Since its identification in 2000, inhibitors covering many different structural classes have been designed and developed. These inhibitors can be largely classified as either peptidomimetic or non-peptidic inhibitors. Progress in these fields resulted in inhibitors that contain many targeted drug-like characteristics. In this review, we describe structure-based design strategies and evolution of a wide range of BACE1 inhibitors including compounds that have been shown to reduce brain A beta, rescue the cognitive decline in transgenic AD mice and inhibitor drug candidates that are currently in clinical trials.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据